September 1, 2024
Implant Surgery Articles
September 1, 2024
Surgical Tips for Combined Angle-based Minimally Invasive Glaucoma Procedures
By Zachary Vest, MD
September 1, 2024
Spotlight: An Option for Interventional Glaucoma
By Karen Appold, contributing writer
June 1, 2024
Intraoperative OCT in Glaucoma Surgery
By Syril K. Dorairaj, MD, and, Bryan C. H. Ang, MBBS, FAMS, FRCOphth, P. Connor Lentz, BS
June 1, 2024
Positive Travoprost Implant Data Presented at ASCRS
By Conni Koury, contributing editor
June 1, 2024
Data on IOL-based Delivery of Bimatoprost Presented at ASCRS
By Conni Koury, contributing editor
April 19, 2024
Permanent J-code Assigned for iDose TR
By Jim Gallagher, managing editor
March 1, 2024
Biodegradable Latanoprost Implant Promising in Phase 2a
By Conni Koury, contributing editor
March 1, 2024
SpyGlass Pharma's Long-term Bimatoprost Implant Studied in Phase 1/2 Trial
By Conni Koury, contributing editor
March 1, 2024
Travoprost Implant Noninferior to Twice-daily Timolol 0.5% Drops
By Conni Koury, contributing editor
March 1, 2024
Travoprost Implant Lowered IOP Better Than Topical PGA Monotherapy
By Conni Koury, contributing editor
March 1, 2024
No Significant ECD Loss Seen With Travoprost Implant
By Conni Koury, contributing editor
March 1, 2024
Surgical Exchange of Travoprost Implant Safe
By Conni Koury, contributing editor
March 1, 2024
At 3 Years IOP Controlled in More Subjects With Travoprost Implant vs Topical Timolol
By Conni Koury, contributing editor
March 1, 2024
Combined Trabecular Microbypass and Goniotomy Effective
By Conni Koury, contributing editor
March 1, 2024
Sustained-delivery Glaucoma Treatments
By Galia Deitz, MD, Cara E. Capitena-Young, MD
December 18, 2023
Glaukos iDose TR Gets FDA Approval
By Conni Koury, contributing editor
December 1, 2023
Intravitreal Implant Moves to Phase 2a
By Conni Koury, contributing editor
December 1, 2023
Generic Brimonidine 0.1% Launched
By Conni Koury, contributing editor
December 1, 2023
Miniject Safe and Effective at 3 Years
By Conni Koury, contributing editor
September 1, 2023
FDA Accepts NDA for iDose TR
By Conni Koury, contributing editor
June 1, 2023
An Update on Robotic Surgery for Glaucoma
By Joseph F. Panarelli, MD, Eileen C. Bowden, MD
March 1, 2023
Treatment of Severe Ocular Surface Disease in the Glaucoma Patient
By Laura Voicu, MD, Sarwat Salim, MD, FACS
March 1, 2023
Results for iDose TR Exchange Trial Show Good Safety and Tolerability
By Conni Koury, contributing editor
December 1, 2022
SpyGlass Pharma Presents First-in-human Data on IOL-based Drug-delivery Platform
By Conni Koury, contributing editor
December 1, 2022
Phase 3 Study of Glaukos iDose TR Met Primary Efficacy Endpoints
By Conni Koury, contributing editor
September 1, 2022
From the Editor: Five Years of Glaucoma Physician
By Nathan M. Radcliffe, MD
September 1, 2022
Greater Than 80% Uptick in Glaucoma Surgeries in Recent Years
By Conni Koury, contributing editor
June 1, 2022
Update on Current Surgical Management of Pediatric Glaucoma
By Rebecca F. Neustein, MD, MARLENE R. MOSTER, M.D.
June 1, 2022
FDA Clears Glaukos iPrime
By Conni Koury, contributing editor
June 1, 2022
Injectsense Awarded $1.7M Grant From NIH for Implantable Autonomous IOP Sensor
By Conni Koury, contributing editor
March 1, 2022
Tips and Tricks for Bleb Needling
By Sahar Bedrood, MD, PhD
March 1, 2022
From the Editor: The Glaucoma Patient Journey
By Nathan M. Radcliffe, MD
March 1, 2022
Study: Durysta Bimatoprost Implant Effective for OAG, Ocular Hypertension
By Conni Koury, contributing editor
March 1, 2022
Intermediate Outcomes Are Positive for Aurolab Aqueous Drainage Implant in NVG
By Conni Koury, contributing editor
December 1, 2020
Early-stage Sustained-release Implant Uses Latanoprost
By Jerry Helzner, contributing editor
September 1, 2020
Tips and Tricks for Durysta Injection
By E. Randy Craven, MD
June 1, 2020
Ocular Therapeutix: Positive Data on Long-Term Implant
By Jerry Helzner, contributing editor
June 1, 2020
New, Detailed Phase 3 Data on Durysta Implant Presented at ASCRS
By Jerry Helzner, contributing editor
March 6, 2020
FDA Approves Breakthrough Sustained-Release Glaucoma Implant
By Jerry Helzner, contributing editor
March 4, 2020
Second Phase 3 Trial Validates Efficacy of Bimatoprost SR
By Jerry Helzner, contributing editor